Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies.

abstract：:Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

journal_title：Hematological oncology

authors： Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

更新日期：2019-10-01 00:00:00

abstract：:The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...

journal_title：Hematological oncology

authors： McMullin MF

更新日期：2007-06-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

journal_title：Hematological oncology

authors： Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

更新日期：2017-12-01 00:00:00

abstract：:The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...

journal_title：Hematological oncology

authors： Fozza C

更新日期：2018-02-01 00:00:00

abstract：:Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

journal_title：Hematological oncology

authors： Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

更新日期：2016-12-01 00:00:00

abstract：:In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

journal_title：Hematological oncology

authors： Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

更新日期：2019-10-01 00:00:00

abstract：:Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...

journal_title：Hematological oncology

authors： Barbui T,Bassan R,Chisesi T,Battista R,Cortelazzo S,Rodeghiero F,Capnist G,D'Emilio A,Viero P,Dini E

更新日期：1985-01-01 00:00:00

abstract：:Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...

journal_title：Hematological oncology

authors： Albano D,Bosio G,Orlando E,Bertagna F

更新日期：2017-12-01 00:00:00

abstract：:Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

journal_title：Hematological oncology

authors： Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

更新日期：2020-10-01 00:00:00

abstract：:This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...

journal_title：Hematological oncology

authors： Cartwright RA,Gilman EA,Nicholson P,Allon D

更新日期：1999-03-01 00:00:00

abstract：:Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

journal_title：Hematological oncology

authors： Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

更新日期：2016-03-01 00:00:00

abstract：:Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

journal_title：Hematological oncology

authors： Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

更新日期：2008-03-01 00:00:00

abstract：:Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...

journal_title：Hematological oncology

authors： Hussein S,Gill K,Baer LN,Hoehn D,Mansukhani M,Jobanputra V,Bhagat G,Alobeid B

更新日期：2015-03-01 00:00:00

abstract：:The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

journal_title：Hematological oncology

authors： Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

更新日期：1997-08-01 00:00:00

abstract：:The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

journal_title：Hematological oncology

authors： Gustavsson A,Olofsson T,Olsson I

更新日期：1984-04-01 00:00:00

abstract：:Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

journal_title：Hematological oncology

authors： Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

更新日期：2015-06-01 00:00:00

abstract：:The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

journal_title：Hematological oncology

authors： Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

更新日期：2015-09-01 00:00:00

abstract：:ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...

journal_title：Hematological oncology

authors： Abbott BL

更新日期：2003-09-01 00:00:00

abstract：:Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

journal_title：Hematological oncology

authors： Ma SK,Wan TS,Chan LC

更新日期：1999-09-01 00:00:00

abstract：:Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...

journal_title：Hematological oncology

authors： Oza AM,Leahy M,Dorey E,Davis CL,Amess J,Horton M,Rohatiner AZ,Wrigley PF,Lister TA

更新日期：1991-11-01 00:00:00

abstract：:Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...

journal_title：Hematological oncology

authors： Martinelli G,Iacobucci I,Soverini S,Cilloni D,Saglio G,Pane F,Baccarani M

更新日期：2006-12-01 00:00:00

abstract：:Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

journal_title：Hematological oncology

authors： Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

更新日期：1992-11-01 00:00:00

abstract：:High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Trea...

journal_title：Hematological oncology

authors： Cocorocchio E,Peccatori F,Vanazzi A,Piperno G,Calabrese L,Botteri E,Travaini L,Preda L,Martinelli G

更新日期：2013-03-01 00:00:00

abstract：:B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

journal_title：Hematological oncology

authors： Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

更新日期：2008-12-01 00:00:00

abstract：:Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...

journal_title：Hematological oncology

authors： Ugai T,Matsuo K,Oze I,Ito H,Wakai K,Wada K,Nagata C,Nakayama T,Liu R,Kitamura Y,Tamakoshi A,Tsuji I,Sugawara Y,Sawada N,Sadakane A,Tanaka K,Mizoue T,Inoue M,Tsugane S,Shimazu T,Research Group for the Development a

更新日期：2018-02-01 00:00:00

abstract：:Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

journal_title：Hematological oncology

authors： Tsang M,Cleveland J,Rubenstein JL

更新日期：2020-12-01 00:00:00

abstract：:The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...

journal_title：Hematological oncology

authors： Santoro M,Accurso V,Mancuso S,Carlisi M,Raso S,Tarantino G,Di Piazza F,Perez A,Russo A,Siragusa S

更新日期：2019-10-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver...

journal_title：Hematological oncology

authors： Fang Y,Pinkney KA,Lee JC,Gindin T,Weiner MA,Alobeid B,Bhagat G

更新日期：2013-03-01 00:00:00

abstract：:Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

journal_title：Hematological oncology

authors： Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

更新日期：2015-12-01 00:00:00